GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (CHIX:RLFz) » Definitions » 12-1 Month Momentum %

Relief Therapeutics Holding (CHIX:RLFZ) 12-1 Month Momentum % : 261.14% (As of Dec. 14, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Relief Therapeutics Holding 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-14), Relief Therapeutics Holding's 12-1 Month Momentum % is 261.14%.

The industry rank for Relief Therapeutics Holding's 12-1 Month Momentum % or its related term are showing as below:

CHIX:RLFz's 12-1 Month Momentum % is ranked better than
97.58% of 1447 companies
in the Biotechnology industry
Industry Median: -15.46 vs CHIX:RLFz: 261.14

Competitive Comparison of Relief Therapeutics Holding's 12-1 Month Momentum %

For the Biotechnology subindustry, Relief Therapeutics Holding's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's 12-1 Month Momentum % falls into.



Relief Therapeutics Holding  (CHIX:RLFz) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relief Therapeutics Holding  (CHIX:RLFz) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Relief Therapeutics Holding 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

Relief Therapeutics Holding Headlines

No Headlines